Trial · NCT03364335
Outcomes13
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 13 of 13
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Percentage Body Weight Change | Baseline to Day 168 | ANCOVA Analysis for Primary Endpoint - Percent Change in Body Weight from Baseline to Day 168 in per protocol population. | percentage | MEAN |
| SECONDARY | Change in Absolute Body Weight | Baseline to Day 168 | ANCOVA Analysis for Secondary Endpoint - Change in Absolute Body Weight from Baseline to day 168 (Per-Protocol Population). | kg | MEAN |
| SECONDARY | Change in Percentage of Patients With ≥5% Body Weight Loss | Baseline to Day 168 | Analysis for Secondary Endpoint - Percentage of Subjects with ≥5% Relative Percentage Reduction from Baseline to day 168 in Body Weight by Treatment (Per-Protocol Population). | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Change in Waist Circumference | Baseline to Day 168 | ANCOVA Analysis for Secondary Endpoint - Change in Waist Circumference from Baseline (Per-Protocol Population). | cm | MEAN |
| SECONDARY | Change in Total Cholesterol | Baseline to Day 168 | ANCOVA Analysis for Secondary Endpoint - Change in Fasting Plasma Lipids from Baseline to day 168 (Per-Protocol Population). | mg/dL | MEAN |
| SECONDARY | Change in HDL Cholesterol | Baseline, Day 168 | ANCOVA Analysis for Secondary Endpoint - Change in Fasting Plasma Lipids from Baseline to day 168 (Per-Protocol Population). | mg/dL | MEAN |
| SECONDARY | Change in LDL Cholesterol | Baseline, 168 days | ANCOVA Analysis for Secondary Endpoint - Change in Fasting Plasma Lipids from Baseline to day 168 (Per-Protocol Population). | mg/dL | MEAN |
| SECONDARY | Change in Triglycerides | Baseline, Day 168 | ANCOVA Analysis for Secondary Endpoint - Change in Fasting Plasma Lipids from Baseline to day 168 (Per-Protocol Population). | mg/dL | MEAN |
| SECONDARY | Change in Plasma Glucose | Baseline to Day 168 | ANCOVA Analysis for Secondary Endpoint - Change in Fasting Plasma Lipids from Baseline to day 168 (Per-Protocol Population). | mg/dL | MEAN |
| SECONDARY | Change in Hemoglobin A1c (HbA1c) | Baseline, Day 168 | ANCOVA Analysis for Secondary Endpoint - Change in HbA1c from Baseline to day 168 (Per-Protocol Population). | percentage of glycosylated hemoglobin | MEAN |
| SECONDARY | Change in Diastolic Blood Pressure | Baseline to Day 168 | ANCOVA Analysis for Secondary Endpoint - Change in Blood Pressure from Baseline to day 168 (Per-Protocol Population) | mmHg | MEAN |
| SECONDARY | Change in Systolic Blood Pressure | Baseline, Day 168 | ANCOVA Analysis for Secondary Endpoint - Change in Blood Pressure from Baseline to day 168 (Per-Protocol Population). | mmHg | MEAN |
| SECONDARY | Change in Inflammatory Markers | Baseline to Day 168 | Descriptive Statistics for Secondary Endpoint - hs-C-Reactive Protein Change from Baseline to day 168 (Per-Protocol Population). | mg/L | MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03364335/outcomes